Le Lézard
Classified in: Health
Subjects: TDS, TRI

Accuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First


SUNNYVALE, Caliornia, February 20, 2018 /PRNewswire/ --

2018 Accuray Conference Focused on Innovative Approaches for Advancing Patient Care, from Curative Treatment to Oligometastases and Palliation  

Accuray Incorporated (NASDAQ: ARAY) announced today highlights from its 2018 European AEROtm (Accuray Exchange in Radiation Oncology) Academy conference held in Lisbon, Portugal on January 26th and 27th.

"Accuray is firmly committed to providing our customers with access to clinical thought leadership and forums that encourage treatment innovation. The AERO Academy events, both in the US and in Europe, are a driving force behind our patient-first philosophy," said Joshua H. Levine, President and Chief Executive Officer at Accuray. "Events like this allow our leadership team to obtain first hand insights into our radiation oncologists' and physicists' needs and their views on how to advance and optimize patient treatment."

These events, which aim to provide an update on current treatment options in the field of advanced radiotherapy, offer a unique opportunity for radiation oncologists and medical physicists from around the world to gather in an exciting educational environment. At the Lisbon event, industry experts engaged in conversations on a broad range of topics including:

"It was an honor to introduce and participate in this year's AERO Academy conference. Patients were truly at the heart of every conversation as we discussed how to innovatively use radiation therapy to deliver highly effective and safe outcomes," said Barbara A. Jereczek-Fossa, M.D., Ph.D., Chair of the Division of Radiotherapy at the European Institute of Oncology and Associate Professor of Radiation Oncology at the University of Milan, Italy. "The conference sessions enabled us to focus on topics that have the potential to positively impact our practice today and in the future. The scope and quality of the scientific exchange resulted in another great instructional meeting."

"We are proud to host this biennial conference dedicated to precision radiation therapy. We believe collaborations with clinicians and scientists are the key to successfully advancing the way radiation therapy is delivered, and ensuring that patients receive the treatment best suited to their particular situation," said Fabienne Hirigoyenberry-Lanson, Ph.D., Vice President Global Medical and Scientific Affairs at Accuray. "We are convinced that the sharing of clinical improvements and technological advancements, as well as peer-to-peer discussion on treatment experiences, encourage innovation, better results and safety in patient care."

About Accuray Exchange in Radiation Oncology (AEROtm)  

AERO includes CyberKnife®Radixacttm and TomoTherapy® System users dedicated to advancing patient care through worldwide clinical and technical partnerships. The AERO community mission is to provide a global forum for the clinical exchange of information between clinicians and physicists for the purpose of setting a new standard in patient care and safety across treatments in the fields of SRS/SBRT, IMRT, IGRT and conventional radiation therapy. Membership to AERO is free and open to all users of the CyberKnife, Radixact and TomoTherapy Systems.

About Accuray 
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com or follow us on FacebookLinkedInTwitter and YouTube.


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: